I forgot to mention, thank you all in advance. And I apologize for potentially flooding the board with this issue but it does make a difference to a lot of investors imo. If people can reply privately it may help. My own DD puts my vote as #3 and leave it to Leo's discretion. The investor part of me votes #1. Cellceutix is a full 100% reporting transparent upfront company in EVERY angle. It doesn't take much to see that. IMO.
I wonder if the change in the listing status requires a filing? No matter, though. I think Leo gave us a heads-up yesterday very similar to the one he delivered in August. For anyone following along it should be obvious that the Brilacidin report will be very good. Big Pharma testing B for prophylactic use? Fantastic news!
Cohort 10? Would anyone have guessed as much two years ago? Thankfully we have Brila to carry the load while we wait for Kevetrin, which is obviously meeting or exceeding expectations.
Market Data 
Markets 
AI
